Clinical Trials: Colon Cancer

Muscle Shoals : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Jonesboro : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Duarte : City of Hope Updated

A Phase II Trial of Radioimmunotherapy (Y-90 M5A) Following Hepatic Resection and FOLFOX Chemotherapy for Metastatic Colorectal Carcinoma to the Liver

Duarte : City of Hope Updated

CALGB/SWOG C80702: A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer

Duarte : City of Hope Updated

Evaluation of Colon/Rectal Cancer Patterns and Outcomes of Care

Duarte : City of Hope Updated

NSABP P-5: Statin Polyp Prevention Trial in Patients with Resected Colon Cancer

Duarte : City of Hope Updated

Phase I Study of Ursodeoxycholic Acid in Combination with 5-Fluorouracil, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Metastatic Colorectal Cancer

Duarte : City of Hope Updated New

Randomised Comparative Study of FOLOX6m Plus SIR-Spheres Microspheres Versus FOLOX6m Alone as First Line Treatment in Patients with Non-Resectable Liver Metastases from Primary Colorectal Carcinoma

Encinitas : Pacific Oncology & Hematology Associates

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.

Glendale : Glendale Adventist Medical Center

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.

Highland : Beaver Medical Group

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.

La Verne : Wilshire Oncology Medical Group

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.

Los Angeles : UCLA

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.

San Diego : Sharp Memorial Hospital

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.

View More »

Anaheim : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Beverly Hills : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Encinitas : Research Site

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Glendale : Glendale Memorial Hospital

A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

Laguna Hills : South Orange County Surgical Medical Group

A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

Long Beach : Long Beach Memorial Medical Center

A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

Roseville : Sutter Roseville Medical Center /Research

A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

Sacramento : UC Davis Cancer Center

A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

Sacramento : Sutter Cancer Center

A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

San Diego : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Stanford : Stanford University School of Medicine

Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies

Aurora : University of Colorado Cancer Center

A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

New Haven : Yale Cancer Center

A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

New Haven : Research Site

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Hudson : ImClone Investigational Site

A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer

Miami : University of Miami

A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

New Port Richey : ImClone Investigational Site

A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer

Port Saint Lucie : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Riverdale : Atlanta Colon and Rectal Surgery

A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

Honolulu : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Elgin : Sherman Health

Adjuvant Colon

Elgin : Sherman Health

CTSU/CALGB 80405: Ph III FOLFOX or FOLFIRI (MD choice) + Beva OR Cetuximab Untx Met Colorectal Wild type K-ras.

Elgin : Sherman Health

NSABP Protocol P-5: Statin Polyp Prevention Trial in Patients with Resected Colon Cancer

Elgin : Sherman Health

Randomized phase III study for stage II colon cancer at high risk for recurrence Comparing 5-FU, leucovorin and Oxalplatin versus 5-FU, leucovorin, oxaliplatin and bevacizumab to determine prospectively the prognostic value of molecular markers

Harvey : Ingalls Memorial Hospital

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.

Skokie : Orchard Research

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.

Skokie : Clintell, Inc.

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.

View More »

Gurnee : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Quincy : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

New Albany : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Waterloo : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Hutchinson : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Crestview Hills : ImClone Investigational Site

A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer

Hazard : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Lexington : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Paducah : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Bethesda : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Cumberland : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Randallstown : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Salisbury : Research Site

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Towson : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Boston : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Saint Louis : Washington University

Adults 50 and older are needed for a cancer research study at Washington University.

View More »

Jefferson City : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

St. Louis : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Grand Island : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Omaha : Research Site

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Portsmouth : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Little Silver : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Somerville : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Albuquerque : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Bronx : Einstein-Montefiore Institute for Clinical & Translational Research

A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

Bronx : Einstein-Montefiore Institute for Clinical & Translational Research

Clinical Investigation Plan STX 0206: Randomised Comparative Study of FOLFOX6m plus SIR-SpheresÒ Microspheres versus FOLFOX6m Alone as First Line Treatment in Patients with Non-Resectable Liver Metastases from Primary Colorectal Carcinoma

New York : Herbert Irving Comprehensive Cancer Center

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.

View More »

Bronx : Albert Einstein College of Medicine, Montefiore Medical Center

A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

Bronx : Montefiore Medical Center - Moses Campus

Exploratory Study Of The ERCC-1 Gene

Bronx : Montefiore Medical Center - Weiler Campus

Exploratory Study Of The ERCC-1 Gene

Bronx : Research Site

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

New York : Research Site

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Nyack : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Charlotte : Presbyterian Hospital Center for Cancer Research

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.

Durham : Duke University Health System

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.

Winston-Salem : Piedmont Hematology Oncology

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.

View More »

Asheville : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Durham : Research Site

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Goldsboro : Research Site

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

High Point : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Winston-Salem : Wake Forest University

A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

Canton : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Cincinnati : ImClone Investigational Site

A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer

Cincinnati : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Columbus : Ohio State University

A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

Fairfield : ImClone Investigational Site

A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer

View More »

Hamilton : ImClone Investigational Site

A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer

Massillon : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Lancaster : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Upland : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

West Reading : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Willow Grove : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Greer : Cancer Center of the Carolinas

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.

View More »

Columbia : ImClone Investigational Site

A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer

Hilton Head Island : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Myrtle Beach : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Memphis : Family Cancer Center

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.

View More »

Franklin : ImClone Investigational Site

A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer

Gallatin : ImClone Investigational Site

A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer

Hermitage : ImClone Investigational Site

A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer

Lebanon : ImClone Investigational Site

A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer

Murfreesboro : ImClone Investigational Site

A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer

Nashville : ImClone Investigational Site

A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer

Nashville : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Smyrna : ImClone Investigational Site

A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer

Houston : S. R. Burzynski Clinic

Phase II Study Of Antineoplaston A10 And AS2-1 Capsules In Patients With Adenocarcinoma Of The Colon

Houston : S. R. Burzynski Clinic

Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Adenocarcinoma Of The Colon

View More »

Corpus Chisti : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Corpus Christi : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Dallas : Mary Crowley Cancer Research Centers

Randomized Phase II Adjuvant Chemotherapy ± FANG™ in Colorectal Carcinoma With Liver Metastases

Houston : MD Anderson Cancer Center

A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

Houston : Research Site

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Abingdon : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Lynchburg : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Kennewick : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Spokane : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Tacoma : Franciscan Research Center

A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

Ballarat : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Coburg : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Footscray : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Frankston : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Hobart : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Feldkirch : Landeskrankenhaus Feldkirch

A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

Linz : Krankenhaus der Elisabethinen

A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

Vienna : Medical University of Vienna

A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

Aalst : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Roeselare : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Verviers : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Sofia : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Varna : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Brampton : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Calgary : ImClone Investigational Site

A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer

Edmonton : ImClone Investigational Site

A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer

Halifax : ImClone Investigational Site

A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer

Hamilton : ImClone Investigational Site

A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer

View More »

Kelowna : ImClone Investigational Site

A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer

Laval : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Levis : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

London : ImClone Investigational Site

A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer

London : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Mississauga : ImClone Investigational Site

A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer

Montreal : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Montréal : ImClone Investigational Site

A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer

Ottawa : ImClone Investigational Site

A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer

Québec : Research Site

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Québec : Research Site

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Sault Ste. Marie : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Sudbury : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Surrey : ImClone Investigational Site

A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer

Toronto : ImClone Investigational Site

A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer

Toronto : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Vancouver : ImClone Investigational Site

A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer

Windsor : ImClone Investigational Site

A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer

Hong Kong : University of Hong Kong/ Queen Mary Hospital

A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

Horovice : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Nova Ves pod Plesi : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Olomouc : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Znojmo : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Odense : Odense Universitetshospital

A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

Amiens : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Bordeaux Cedex : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Cahors Cedex : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Lille cedex 01 : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Limoges Cedex : Research Site

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

View More »

Montpellier : CRLC Val d'Aurelle-Paul Lamarque

A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

Montpellier Cedex 5 : Research Site

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Rouen : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Villejuif cedex : Research Site

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Munich : Klinikum Rechts Der Isar

A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

Budapest : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Debrecen : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Gyor : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Gyula : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Kaposvar : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

View More »

Kecskemet : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Szeged : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Szolnok : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Cork : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Dublin : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Galway : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Waterford : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Tel Aviv : Sourasky Medical Center

Clinical Study-evaluate Performance&Safety "Aer-O-Scope" in Colon of Low Risk Patients

Benevento : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Bologna : Research Site

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Firenze (FI) : Research Site

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Milano : Research Site

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Padova : Research Site

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

View More »

Palermo : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Roma : Research Site

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Roma (RM) : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Rozzano (MI) : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Taormina (ME) : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Hamamatsu : Matsuda Hospital

A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

Daugavpils : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Riga : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Colima : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

San Luis Potosi : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Toluca : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Alkmaar : Medisch Centrum Alkmaar

A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

Enschede : Medisch Spectrum Twente

A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

Hoorn : Westfriesgasthuis

A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

Leiden : LUMC

A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

Gdansk : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Lodz : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Olsztyn : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Suwalki : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Warszawa : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

View More »

Warszawa : Research Site

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Bucharest : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Cluj Napoca : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Sibiu : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Chelyabinsk : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Kazan : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Moscow : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Saint Petersburg : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Samara : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

View More »

Yaroslavl : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Bratislava : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Kosice : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Barcelona : Vall d' Hebron University Hospital

A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

L'Hospitalet de Llobregat : IDIBELL Institut Catala d'Oncologia (ICO)

A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

Uppsala : Immunology Akademiska sjukhuset/ University Hospital

A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

Baden : Kantonsspital Baden

A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

Dnipropetrovsk : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Donetsk : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Ivano-Frankivsk : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Kyiv : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Lviv : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

View More »

Uzhgorod : Research Site

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Aberdeen : Aberdeen Royal Infirmary

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.

Belfast, N. Ireland : Cancer Centre

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.

Bournemouth : Royal Bournemouth Hospital

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.

Bristol : Bristol Royal Infirmary

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.

Dorchester, Dorset : Dorset County Hospital

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.

London : Guy's Hospital

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.

Northwood : Mount Vernon Hospital

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.

Romford : Queen's Hospital

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.

Sutton : Royal Marsden Hospital

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.

Whitchurch, Cardiff : Velindre Hospital

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.

View More »

Norwich : Norfolk and Norwich University Hospital

A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

Oxford : University of Oxford

A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

Washington : Georgetown University

A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLOFOX or FOLFIRI

Washington : Georgetown University Hospital

A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint